SHZ Healthcare Medical - Diagnostics & Research 300439.SZ

Medicalsystem Biotechnology Co., Ltd.

$ 8.37 -0.24 %

Medicalsystem Biotechnology Co., Ltd. is a Chinese company focused on delivering clinical diagnostic solutions. Their comprehensive product line includes a full array of reagents and instruments designed for COVID-19 detection, such as PCR, antibody, and antigen test kits, alongside nucleic acid reagents. Beyond infectious disease diagnostics, the company also supplies advanced medical equipment like automated biochemistry analyzers (complete with their corresponding bio-reagents), hematology analyzers, urine analyzers, and glycated hemoglobin analyzers. Additionally, their offerings extend to Point-of-Care Testing (POCT) devices and cutting-edge chemiluminescence immunoassay analyzers. In addition to its diagnostic product offerings, Medicalsystem also provides healthcare services. Initially established in 2003 as Ningbo Medicalsystem Biotechnology Co., Ltd., the company officially adopted its current name, Medicalsystem Biotechnology Co., Ltd., in January 2017. Its corporate headquarters are situated in Ningbo, China.

CEO: Ji Hua Zou - https://www.nbmedicalsystem.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ 10.80

Loading data...

300439.SZ vs S&P500

Loading data...

No data available.

Quick ratio

2.99

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

49.24

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

0.17

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

2.25 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

0.28 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

5.40

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.02

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.24

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

123.22 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
4.60 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
1.07 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.02 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.